March 18th 2024
The decision makes atidarsagene autotemcel the first FDA-approved gene therapy for MLD, a rare genetic disease that affects the brain and nervous system.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
Show Me the Data! Navigating FGFR, FGFR Resistance, Immunotherapy, and a World of Clinical Trials in Cholangiocarcinoma Treatment
View More
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
2024 USCAP Satellite Symposia
March 25-27, 2024
Register Now!
FAQs in Peanut Allergy: Exploring Unanswered Questions Following Allergy Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens
View More
Expert Illustrations & Commentaries™: A Closer Look at Emerging Therapies in IBS-C
View More
4th Annual Live Medical Crossfire® IBS and IBD
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
Medical Crossfire®: Optimizing Treatment Sequencing for HR+/HER2- Metastatic Breast Cancer Based on Emerging Evidence and Evolving Algorithms
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
Earn CME Credits While Advancing Your Expertise in Internal Medicine
April 18-19, 2024
Register Now!
New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?
19 April 2024
Register Now!
Gene Therapy for Hemophilia B—The Next Step Forward in Disease Management
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
BURST Expert Illustrations & Commentaries™: A Closer Look at the Role of Complement Inhibitors in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
View More
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
Neffy epinephrine nasal spray demonstrates positive data in repeat dosing study
February 21st 2024ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).
Safety and efficacy of FDA-approved linaclotide reinforced with new phase 3 data
January 10th 2024Compared to placebo, linaclotide demonstrated a statistically significant and clinically meaningful improvement in spontaneous bowel movement(s) (SBM) frequency rate, and was subsequently approved by the FDA in June 2023.
FDA accepts sBLA for NexoBrid to remove eschar in pediatric thermal burn patients
January 10th 2024MediWound Ltd is seeking to expand the label for NexoBrid, already approved for eschar removal in adult patients, to the pediatric indication after the FDA accepted a supplemental Biologics Application for this patient population.
Marstacimab reduces annualized bleeding in hemophilia A and B patients
January 8th 2024Marstacimab reduced the annualized bleeding rate (ABR) by 35% and nearly 92%, respectively, compared to routine prophylaxis and on-demand treatment in hemophilia A and B patients without inhibitors, according to Pfizer.
FDA approves prescription berdazimer gel, 10.3% to treat molluscum contagiosum
January 5th 2024Berdazimer gel, 10.3% demonstrated positive, topline data in the phase 3 randomized clinical B-SIMPLE4 trial (NCT04535531) that featured a total of 891 patients aged 6 months or older who had 3 to 709 raised molluscum contagiosum lesions.
Emicizumab-kxwh is effective and safe in treating infants with severe hemophilia A
December 13th 2023New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition revealed emicizumab-kxwh (Hemlibra; Genentech) controlled bleeding in babies up to 12 months while demonstrating safety and tolerability.
FDA broadens abatacept usage to include psoriatic arthritis patients aged 2 years and older
November 2nd 2023The FDA has approved abatacept (Orencia) for patients aged ≥2 years with active psoriatic arthritis (PsA), a condition causing joint damage in pediatric patients, offering a new treatment option for juvenile PsA, benefiting young patients, caregivers, and healthcare professionals.